X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Netarsudil 0.02% is known by the name Rhokiinsa® in the European Union, where it is approved for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
The study was designed in accordance with the requirements of Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) to support a potential regulatory submission of netarsudil ophthalmic solution in Japan.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2021
Details:
Data from this study also highlighted THCVHS’ superior IOP-lowering capability and duration of activity as a single agent compared to the current standard of care for the treatment of glaucoma, latanoprost.
Lead Product(s): 9-delta-Tetrahydrocannabinol-valine-hemisuccinate,Netarsudil Mesylate
Therapeutic Area: Ophthalmology Product Name: THC-VHS
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
European Commission has granted a marketing authorisation for Roclanda® 0.02%/0.005% for high intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil are insufficient for IOP reduction.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Aerie Pharmaceuticals successful interim 90-day topline data from its six-month Phase 3b clinical trial in Europe known as Mercury 3, comparing Roclanda® to Ganfort®.
Lead Product(s): Netarsudil Mesylate,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Roclanda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
Aerie expects to hold a meeting with the regulatory authorities in Japan during to discuss Phase 3 trial designs for Rhopressa® while continuing to explore partnership opportunities.
Lead Product(s): Netarsudil Mesylate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
